Inhaltsbereich
| 28 Einträge | 1, 2 › » |
Seite 1 / 2
 Druckansicht
|
| Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML. |
| Blatt K, Herrmann H, Hoermann G, Willmann M, Cerny-Reiterer S, Sadovnik I, Herndlhofer S, Streubel B, Rabitsch W, Sperr WR, Mayerhofer M, Rülicke T, Valent P |
| Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 May 5. pii: 1078-0432.CCR-13-2811. doi: 10.1158/1078-0432.CCR-13-2811 |
| PMID: 24799522 |
| Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. |
| Herrmann H, Sadovnik I, Cerny-Reiterer S, Rülicke T, Stefanzl G, Willmann M, Hoermann G, Bilban M, Blatt K, Herndlhofer S, Mayerhofer M, Streubel B, Sperr WR, Holyoake TL, Mannhalter C, Valent P |
| Blood. 2014 Apr 28. pii: blood-2013-10-536078. doi: 10.1182/blood-2013-10-536078 |
| PMID: 24778155 |
| Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients. |
| Singer J, Fazekas J, Wang W, Weichselbaumer M, Matz M, Mader A, Steinfellner W, Meitz S, Mechtcheriakova D, Sobanov Y, Willmann M, Stockner T, Spillner E, Kunert R, Jensen-Jarolim E |
| Molecular cancer therapeutics. 2014 Apr 22. pii: 1535-7163.MCT-13-0288. doi: 10.1158/1535-7163.MCT-13-0288. pmc: PMC4174294. mid: EMS60298 |
| PMID: 24755200 |
| A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. |
| Saleh R, Wedeh G, Herrmann H, Bibi S, Cerny-Reiterer S, Sadovnik I, Blatt K, Hadzijusufovic E, Jeanningros S, Blanc C, Legarff-Tavernier M, Chapiro E, Nguyen-Khac F, Subra F, Bonnemye P, Dubreuil P, Desplat V, Merle-Béral H, Willmann M, Rülicke T, Valent P, Arock M |
| Blood. 2014 Mar 27. pii: blood-2013-10-534685. doi: 10.1182/blood-2013-10-534685 |
| PMID: 24677542 |
| The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. |
| Peter B, Cerny-Reiterer S, Hadzijusufovic E, Schuch K, Stefanzl G, Eisenwort G, Gleixner KV, Hoermann G, Mayerhofer M, Kundi M, Baumgartner S, Sperr WR, Pickl WF, Willmann M, Valent P |
| Journal of leukocyte biology. 2013 Sep 19. pii: jlb.1112609. doi: 10.1189/jlb.1112609 |
| PMID: 24052572 |
| Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. |
| Singer J, Weichselbaumer M, Stockner T, Mechtcheriakova D, Sobanov Y, Bajna E, Wrba F, Horvat R, Thalhammer JG, Willmann M, Jensen-Jarolim E |
| Molecular immunology. 2012 Mar 19. pii: S0161-5890(12)00003-X. doi: 10.1016/j.molimm.2012.01.002. pmc: PMC3318186 |
| PMID: 22424313 |
| Phylogenetic discordance of human and canine carcinoembryonic antigen (CEA, CEACAM) families, but striking identity of the CEA receptors will impact comparative oncology studies. |
| Weichselbaumer M, Willmann M, Reifinger M, Singer J, Bajna E, Sobanov Y, Mechtcherikova D, Selzer E, Thalhammer JG, Kammerer R, Jensen-Jarolim E |
| PLoS currents. 2011 Mar 16. doi: 10.1371/currents.RRN1223. pii: k/-/-/1glqeci8ut3qh/8. pmc: PMC3059814 |
| PMID: 21436956 |
| Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. |
| Gleixner KV, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, Vales A, Kneidinger M, Samorapoompichit P, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Sillaber C, Willmann M, Valent P |
| Experimental hematology. 2007 Aug 2. pii: S0301-472X(07)00376-1. doi: 10.1016/j.exphem.2007.06.005 |
| PMID: 17681669 |
| IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells. |
| Bauer K, Hadzijusufovic E, Cerny-Reiterer S, Hoermann G, Reifinger M, Pirker A, Valent P, Willmann M |
| Veterinary and comparative oncology. 2016 Aug 9. doi: 10.1111/vco.12260 |
| PMID: 27507155 |
| The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma. |
| Keller A, Wingelhofer B, Peter B, Bauer K, Berger D, Gamperl S, Reifinger M, Cerny-Reiterer S, Moriggl R, Willmann M, Valent P, Hadzijusufovic E |
| Veterinary and comparative oncology. 2017 Apr 11. doi: 10.1111/vco.12311 |
| PMID: 28397975 |
| Evaluation of cooperative anti-leukemic effects of nilotinib and vildagliptin in Ph(+) chronic myeloid leukemia. |
| Willmann M, Sadovnik I, Eisenwort G, Entner M, Bernthaler T, Stefanzl G, Hadzijusufovic E, Berger D, Herrmann H, Hoermann G, Valent P, Rülicke T |
| Experimental hematology. 2017 Oct 12. pii: S0301-472X(17)30816-0. doi: 10.1016/j.exphem.2017.09.012 |
| PMID: 29031704 |
| Development of a radiolabeled caninized anti-EGFR antibody for comparative oncology trials. |
| Fazekas-Singer J, Berroterán-Infante N, Rami-Mark C, Dumanic M, Matz M, Willmann M, Andreae F, Singer J, Wadsak W, Mitterhauser M, Jensen-Jarolim E |
| Oncotarget. 2017 Sep 15. doi: 10.18632/oncotarget.20914. pii: 20914. pmc: PMC5669955 |
| PMID: 29137329 |
| Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. |
| Peter B, Bibi S, Eisenwort G, Wingelhofer B, Berger D, Stefanzl G, Blatt K, Herrmann H, Hadzijusufovic E, Hoermann G, Hoffmann T, Schwaab J, Jawhar M, Willmann M, Sperr WR, Zuber J, Sotlar K, Horny HP, Moriggl R, Reiter A, Arock M, Valent P |
| Leukemia. 2017 Dec 18. pii: leu2017338. doi: 10.1038/leu.2017.338 |
| PMID: 29249817 |
| Expression of vascular endothelial growth factor and its receptors in canine lymphoma. |
| Wolfesberger B, Guija de Arespacohaga A, Willmann M, Gerner W, Miller I, Schwendenwein I, Kleiter M, Egerbacher M, Thalhammer JG, Muellauer L, Skalicky M, Walter I |
| Journal of comparative pathology. 2007 Apr 27. pii: S0021-9975(07)00032-1. doi: 10.1016/j.jcpa.2007.03.003 |
| PMID: 17467003 |
| Phenotyping and Target Expression Profiling of CD34/CD38 and CD34/CD38 Stem- and Progenitor cells in Acute Lymphoblastic Leukemia. |
| Blatt K, Menzl I, Eisenwort G, Cerny-Reiterer S, Herrmann H, Herndlhofer S, Stefanzl G, Sadovnik I, Berger D, Keller A, Hauswirth A, Hoermann G, Willmann M, Rülicke T, Sill H, Sperr WR, Mannhalter C, Melo JV, Jäger U, Sexl V, Valent P |
| Neoplasia (New York, N.Y.). 2018 May 14. pii: S1476-5586(18)30088-5. doi: 10.1016/j.neo.2018.04.004 |
| PMID: 29772458 |
| Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives. |
| Valent P, Hadzijusufovic E, Grunt T, Karlic H, Peter B, Herrmann H, Eisenwort G, Hoermann G, Schulenburg A, Willmann M, Hubmann R, Shehata M, Selzer E, Gleixner KV, Rülicke T, Sperr WR, Marian B, Pfeilstöcker M, Pehamberger H, Keil F, Jäger U, Zielinski C |
| Wiener klinische Wochenschrift. 2018 Jul 13. doi: 10.1007/s00508-018-1355-7. pii: 10.1007/s00508-018-1355-7 |
| PMID: 30006759 |
| Comparative Oncology: the Paradigmatic Example of Canine and Human Mast Cell Neoplasms. |
| Willmann M, Hadzijusufovic E, Hermine O, Dacasto M, Marconato L, Bauer K, Peter B, Gamperl S, Eisenwort G, Jensen-Jarolim E, Müller M, Arock M, Vail DM, Valent P |
| Veterinary and comparative oncology. 2018 Aug 22. doi: 10.1111/vco.12440 |
| PMID: 30136349 |
| Identification of a leukemia-initiating stem cell in human mast cell leukemia. |
| Eisenwort G, Sadovnik I, Schwaab J, Jawhar M, Keller A, Stefanzl G, Berger D, Blatt K, Hoermann G, Bilban M, Willmann M, Winding C, Sperr WR, Arock M, Rülicke T, Reiter A, Valent P |
| Leukemia. 2019 Apr 5. doi: 10.1038/s41375-019-0460-6. pii: 10.1038/s41375-019-0460-6 |
| PMID: 30953030 |
| Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells. |
| Gamperl S, Stefanzl G, Peter B, Smiljkovic D, Bauer K, Willmann M, Valent P, Hadzijusufovic E |
| Veterinary and comparative oncology. 2019 Jul 8. doi: 10.1111/vco.12520 |
| PMID: 31286638 |
| In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells. |
| Gamperl S, Stefanzl G, Willmann M, Valent P, Hadzijusufovic E |
| Veterinary medicine and science. 2020 Sep 13. doi: 10.1002/vms3.336 |
| PMID: 32924324 |
| 28 Einträge | 1, 2 › » |
Seite 1 / 2
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
